Evaluation of programmed cell death ligand 1 expression in a contemporary cohort of penile squamous cell carcinoma and its correlation with clinicopathologic and survival parameters : A study of 134 patients
© The Author(s) 2023. Published by Oxford University Press on behalf of American Society for Clinical Pathology. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com..
OBJECTIVES: Penile squamous cell carcinomas (PCs) are rare malignancies with a dismal prognosis in a metastatic setting; therefore, novel immunotherapeutic modalities are an unmet need. One such modality is the immune checkpoint molecule programmed cell death ligand 1 (PD-L1). We sought to analyze PD-L1 expression and its correlation with various clinicopathologic parameters in a contemporary cohort of 134 patients with PC.
METHODS: A cohort of 134 patients with PC was studied for PD-L1 immunohistochemistry. The PD-L1 expression was evaluated using a combined proportion score with a cutoff of 1 or higher to define positivity. The results were correlated with various clinicopathologic parameters.
RESULTS: Overall, 77 (57%) patients had positive PD-L1 expression. Significantly high PD-L1 expression was observed in high-grade tumors (P = .006). We found that 37% of human papillomavirus (HPV)-associated subtypes and 73% of other histotype tumors expressed PD-L1, while 63% of HPV-associated tumors and 27% of other histotype tumors did not (odds ratio, 1.35; P = .002 when compared for HPV-associated groups vs all others). Similarly, PD-L1-positive tumors had a 3.61-times higher chance of being node positive than PD-L1-negative tumors (P = .0009). In addition, PD-L1 high-positive tumors had a 5-times higher chance of being p16ink4a negative than PD-L1 low-positive tumors (P = .004). The PD-L1-positive tumors had a lower overall survival and cancer-specific survival than PD-L1-negative tumors.
CONCLUSIONS: Overall, PD-L1 expression is associated with high-grade and metastatic tumors. Lower PD-L1 expression is observed more frequently in HPV-associated (warty or basaloid) subtypes than in other, predominantly HPV-independent types. As a result, PD-L1 positivity, including higher expression, portends lower overall and cancer-specific survival. These data provide a rational for further investigating PD-L1-based immunotherapeutics in PC.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:161 |
|---|---|
| Enthalten in: |
American journal of clinical pathology - 161(2024), 1 vom: 04. Jan., Seite 49-59 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lobo, Anandi [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
B7-H1 Antigen |
|---|
| Anmerkungen: |
Date Completed 05.01.2024 Date Revised 05.01.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/ajcp/aqad107 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM361377789 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM361377789 | ||
| 003 | DE-627 | ||
| 005 | 20240108142047.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/ajcp/aqad107 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1249.xml |
| 035 | |a (DE-627)NLM361377789 | ||
| 035 | |a (NLM)37639681 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lobo, Anandi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Evaluation of programmed cell death ligand 1 expression in a contemporary cohort of penile squamous cell carcinoma and its correlation with clinicopathologic and survival parameters |b A study of 134 patients |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.01.2024 | ||
| 500 | |a Date Revised 05.01.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2023. Published by Oxford University Press on behalf of American Society for Clinical Pathology. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com. | ||
| 520 | |a OBJECTIVES: Penile squamous cell carcinomas (PCs) are rare malignancies with a dismal prognosis in a metastatic setting; therefore, novel immunotherapeutic modalities are an unmet need. One such modality is the immune checkpoint molecule programmed cell death ligand 1 (PD-L1). We sought to analyze PD-L1 expression and its correlation with various clinicopathologic parameters in a contemporary cohort of 134 patients with PC | ||
| 520 | |a METHODS: A cohort of 134 patients with PC was studied for PD-L1 immunohistochemistry. The PD-L1 expression was evaluated using a combined proportion score with a cutoff of 1 or higher to define positivity. The results were correlated with various clinicopathologic parameters | ||
| 520 | |a RESULTS: Overall, 77 (57%) patients had positive PD-L1 expression. Significantly high PD-L1 expression was observed in high-grade tumors (P = .006). We found that 37% of human papillomavirus (HPV)-associated subtypes and 73% of other histotype tumors expressed PD-L1, while 63% of HPV-associated tumors and 27% of other histotype tumors did not (odds ratio, 1.35; P = .002 when compared for HPV-associated groups vs all others). Similarly, PD-L1-positive tumors had a 3.61-times higher chance of being node positive than PD-L1-negative tumors (P = .0009). In addition, PD-L1 high-positive tumors had a 5-times higher chance of being p16ink4a negative than PD-L1 low-positive tumors (P = .004). The PD-L1-positive tumors had a lower overall survival and cancer-specific survival than PD-L1-negative tumors | ||
| 520 | |a CONCLUSIONS: Overall, PD-L1 expression is associated with high-grade and metastatic tumors. Lower PD-L1 expression is observed more frequently in HPV-associated (warty or basaloid) subtypes than in other, predominantly HPV-independent types. As a result, PD-L1 positivity, including higher expression, portends lower overall and cancer-specific survival. These data provide a rational for further investigating PD-L1-based immunotherapeutics in PC | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a PD-L1 | |
| 650 | 4 | |a cancer-specific survival | |
| 650 | 4 | |a overall survival | |
| 650 | 4 | |a penile | |
| 650 | 4 | |a squamous cell carcinoma | |
| 650 | 7 | |a B7-H1 Antigen |2 NLM | |
| 650 | 7 | |a Ligands |2 NLM | |
| 650 | 7 | |a Biomarkers, Tumor |2 NLM | |
| 700 | 1 | |a Mishra, Sourav K |e verfasserin |4 aut | |
| 700 | 1 | |a Jha, Shilpy |e verfasserin |4 aut | |
| 700 | 1 | |a Tiwari, Ankit |e verfasserin |4 aut | |
| 700 | 1 | |a Kapoor, Rahul |e verfasserin |4 aut | |
| 700 | 1 | |a Sharma, Shivani |e verfasserin |4 aut | |
| 700 | 1 | |a Kaushal, Seema |e verfasserin |4 aut | |
| 700 | 1 | |a Kiranmai, N Sri |e verfasserin |4 aut | |
| 700 | 1 | |a Das, M Rakshitha |e verfasserin |4 aut | |
| 700 | 1 | |a Peddinti, Kamal P |e verfasserin |4 aut | |
| 700 | 1 | |a Sharma, Shailendra K |e verfasserin |4 aut | |
| 700 | 1 | |a Bhardwaj, Nitin |e verfasserin |4 aut | |
| 700 | 1 | |a Arora, Samriti |e verfasserin |4 aut | |
| 700 | 1 | |a Jain, Deepika |e verfasserin |4 aut | |
| 700 | 1 | |a Jain, Ekta |e verfasserin |4 aut | |
| 700 | 1 | |a Munjal, Gauri |e verfasserin |4 aut | |
| 700 | 1 | |a Shinde, Sayali |e verfasserin |4 aut | |
| 700 | 1 | |a Malik, Vipra |e verfasserin |4 aut | |
| 700 | 1 | |a Singh, Hena |e verfasserin |4 aut | |
| 700 | 1 | |a Varshney, Juhi |e verfasserin |4 aut | |
| 700 | 1 | |a Pradhan, Dinesh |e verfasserin |4 aut | |
| 700 | 1 | |a Dixit, Mallika |e verfasserin |4 aut | |
| 700 | 1 | |a Pattnaik, Niharika |e verfasserin |4 aut | |
| 700 | 1 | |a Sharma, Ashish K |e verfasserin |4 aut | |
| 700 | 1 | |a Barapatre, Yogesh R |e verfasserin |4 aut | |
| 700 | 1 | |a Pradhan, Manas |e verfasserin |4 aut | |
| 700 | 1 | |a Satapathy, Kaliprasad |e verfasserin |4 aut | |
| 700 | 1 | |a Rath, Debadarshi |e verfasserin |4 aut | |
| 700 | 1 | |a Jaiswal, Sunil |e verfasserin |4 aut | |
| 700 | 1 | |a Das, Stithi |e verfasserin |4 aut | |
| 700 | 1 | |a Khadenga, Chiraranjan |e verfasserin |4 aut | |
| 700 | 1 | |a Routa, Sudhasmita |e verfasserin |4 aut | |
| 700 | 1 | |a Baisakh, Manas R |e verfasserin |4 aut | |
| 700 | 1 | |a Tiwari, Romila |e verfasserin |4 aut | |
| 700 | 1 | |a Sampat, Nakul Y |e verfasserin |4 aut | |
| 700 | 1 | |a Chakrabarti, Indranil |e verfasserin |4 aut | |
| 700 | 1 | |a Parwani, Anil V |e verfasserin |4 aut | |
| 700 | 1 | |a Mohanty, Sambit K |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t American journal of clinical pathology |d 1945 |g 161(2024), 1 vom: 04. Jan., Seite 49-59 |w (DE-627)NLM000037001 |x 1943-7722 |7 nnns |
| 773 | 1 | 8 | |g volume:161 |g year:2024 |g number:1 |g day:04 |g month:01 |g pages:49-59 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/ajcp/aqad107 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 161 |j 2024 |e 1 |b 04 |c 01 |h 49-59 | ||